What is ARA-290?
ARA-290, also called cibinetide, is an erythropoietin-derived peptide investigated in tissue-protection research. A small clinical pilot examined neuropathy symptoms in people with sarcoidosis.
Biological role or research focus
Small-fiber neuropathy research.
A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
Role reference: Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. · 2012 ↗
Names you may encounter
Cibinetide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Erythropoietin-derived investigational peptide
- Research focus
- Small-fiber neuropathy research
- Featured evidence
- Human randomized pilot trial
- Source check
- October 4, 2026
Quick answers
- Is ARA-290 FDA approved?
- No. No FDA-approved drug contains ARA-290. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
- Is ARA-290 safe?
- ARA-290 (cibinetide) is an investigational EPO-derived peptide. Small, short neuropathy trials did not identify safety problems, but rare and long-term risks are unknown. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is ARA-290 banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S2.1.5 Innate repair receptor agonists). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Sarcoidosis-associated small-fiber neuropathy pilot (2012) | Human randomized pilot trial | 22 people with sarcoidosis and small-fiber neuropathy. |
| ARA 290 · nerve-fiber outcomes (2013) | Human placebo-controlled trial | Patients with sarcoidosis and documented small nerve-fiber loss; the abstract does not state the sample size. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized pilot trial · 2012
Sarcoidosis-associated small-fiber neuropathy pilot
What did this publication test, and what did it find?
- Population / model
- 22 people with sarcoidosis and small-fiber neuropathy.
- Study design
- Randomized double-blind placebo-controlled pilot over four weeks.
- Main finding
- The small-fiber-neuropathy symptom score improved more with ARA-290. Brief Pain Inventory pain and fatigue measures improved similarly in both groups; depression did not change.
- Limits & context
- A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
Human placebo-controlled trial · 2013
ARA 290 · nerve-fiber outcomes
Did a later short study add objective nerve measures?
- Population / model
- Patients with sarcoidosis and documented small nerve-fiber loss; the abstract does not state the sample size.
- Study design
- Blinded placebo comparison over 28 days, assessing neuropathic symptoms, corneal nerve density, sensory testing, and walking capacity.
- Main finding
- The report described improved neuropathic symptoms, increased corneal small nerve-fiber density, altered temperature sensitivity, and greater six-minute walking capacity.
- How to read it
- An objective corneal measure complements symptom reports but is not proof of durable recovery throughout the nervous system.
- Limits & context
- The abstract omits effect sizes and participant count. Short follow-up and a specific disease setting limit generalization. Full methods and longer-term replication need review before making a disease-modifying claim.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
2 registered studies name ARA-290 as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 1 completed and 1 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis NCT02039687 · Araim Pharmaceuticals, Inc. | Completed | Phase 2 | 2014-01 | 64 |
| ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) NCT01933529 · Claes-Göran Östenson | Status unknown | Phase 2 | 2013-10 | 24 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
ARA-290 (cibinetide) is an investigational EPO-derived peptide. Small, short neuropathy trials did not identify safety problems, but rare and long-term risks are unknown.
Placebo-controlled trials lasting about a month in people with sarcoidosis-related nerve damage, plus a small type 2 diabetes study, reported no safety concerns. They were too small and brief to detect uncommon or delayed harms.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: ARA 290 in sarcoidosis small-fiber neuropathy: pilot trial (2012) ↗ · Cibinetide phase 2b trial in sarcoidosis nerve-fiber loss (2017) ↗ · ARA 290 in type 2 diabetes with neuropathy (2015) ↗
Safety & what remains unknown
The pilot did not identify a clinical or laboratory safety concern, but its size and duration provide limited information about uncommon or delayed harms.
Evidence boundaries
A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 3 (nominated without enough support)
Listed in 503A category 3 as "Cibinetide (ARA-290)" (nominated without adequate support); not eligible for the category 1 interim policy. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S2.1.5 Innate repair receptor agonists
Not named, but cibinetide is an innate repair receptor agonist, a class prohibited under S2.1.5 (likely covered). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The featured trial concerns sarcoidosis-associated small-fiber neuropathy. It does not establish effectiveness for every form of pain, neuropathy, or injury.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
Its design separates proposed tissue-protective signaling from erythropoietin’s red-blood-cell effects. The pilot measured clinical symptoms rather than establishing nerve regeneration.
Questions worth asking
- Did every pain outcome improve more than placebo?
- What material, population, and route were actually studied?
- A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Did every pain outcome improve more than placebo?
No. The report distinguished an improved neuropathy symptom score from pain and fatigue measures that improved similarly in both groups.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
